Privileged scaffolds as MAO inhibitors: Retrospect and prospects
This review aims to be a comprehensive, authoritative, critical, and readable review of
general interest to the medicinal chemistry community because it focuses on the …
general interest to the medicinal chemistry community because it focuses on the …
Pediatric multiple sclerosis
Pediatric multiple sclerosis (MS) accounts for up to 5% of all MS cases. Work conducted over
the past 5 years has provided new information about the treatment, pathogenesis …
the past 5 years has provided new information about the treatment, pathogenesis …
Defining the response to interferon‐β in relapsing‐remitting multiple sclerosis patients
J Río, C Nos, M Tintoré, N Téllez, I Galán… - Annals of Neurology …, 2006 - Wiley Online Library
Objective Many patients with multiple sclerosis (MS) are currently receiving treatment with
interferon (IFN)–β. Early identification of nonresponder patients is crucial to try different …
interferon (IFN)–β. Early identification of nonresponder patients is crucial to try different …
Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis
T Chitnis, S Tenembaum, B Banwell… - Multiple Sclerosis …, 2012 - journals.sagepub.com
New therapies are being evaluated by clinical trials and, if efficacious, introduced for the
treatment of adult MS. The role of these new and existing agents in the management of …
treatment of adult MS. The role of these new and existing agents in the management of …
Early relapses, onset of progression, and late outcome in multiple sclerosis
A Scalfari, A Neuhaus, M Daumer, GC DeLuca… - JAMA …, 2013 - jamanetwork.com
Objectives To investigate the relationship among attacks in the first 2 years (early relapses),
secondary progression (SP), and late disability in multiple sclerosis (MS). Design Cohort …
secondary progression (SP), and late disability in multiple sclerosis (MS). Design Cohort …
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis
Background: Currently available disease-modifying therapies (DMTs) are known to be only
partially effective in adults with multiple sclerosis (MS). Little is known about pediatric …
partially effective in adults with multiple sclerosis (MS). Little is known about pediatric …
Therapy of MS
R Vosoughi, MS Freedman - Clinical neurology and neurosurgery, 2010 - Elsevier
The era of disease-modifying drugs (DMDs) in multiple sclerosis (MS) treatment began in
the 1990s, first with interferon-β (IFNβ), and the number of agents has increased steadily …
the 1990s, first with interferon-β (IFNβ), and the number of agents has increased steadily …
Dynamic learning of patient response types: An application to treating chronic diseases
Currently available medication for treating many chronic diseases is often effective only for a
subgroup of patients, and biomarkers accurately assessing whether an individual belongs to …
subgroup of patients, and biomarkers accurately assessing whether an individual belongs to …
Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician
Several lines of evidence link immunosuppression to inflammation in patients with multiple
sclerosis (MS) and provide a rationale for the increasing use of immunosuppressive drugs in …
sclerosis (MS) and provide a rationale for the increasing use of immunosuppressive drugs in …
[HTML][HTML] Disease-modifying therapy of pediatric multiple sclerosis
T Chitnis - Neurotherapeutics, 2013 - Elsevier
Multiple sclerosis (MS) is increasingly recognized in children and adolescents. Improved
awareness, access to care, and subspecialty training in pediatric MS has allowed for better …
awareness, access to care, and subspecialty training in pediatric MS has allowed for better …